NCT03729297 (Cabo ASAP) is a Phase 2 clinical trial of Cabozantinib in Salivary Gland Cancer, sponsored by Radboud University Medical Center.

Who is sponsoring NCT03729297?

NCT03729297 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03729297?

Interventions in NCT03729297: Cabozantinib.

What condition does NCT03729297 study?

NCT03729297 studies Salivary Gland Cancer.

Is NCT03729297 still recruiting?

NCT03729297 is currently terminated. Last updated 12 March 2021.

Last reviewed 2021-03-12 · How we verify

NCT03729297: Cabo ASAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib in Advanced Salivary Gland Cancer Patients

Terminated Phase 2 Last updated 12 March 2021

What this trial tests

Phase 2 trial testing Cabozantinib in Salivary Gland Cancer in 25 participants. Terminated before completion.

Timeline

5 September 2018

Primary endpoint
6 November 2019

6 November 2019

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	5 September 2018
Primary completion	6 November 2019
Estimated completion	6 November 2019
Sites	1 location across Netherlands

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Salivary Gland Cancer — all drugs for Salivary Gland Cancer →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Salivary Gland Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 2 clinical trial on the efficacy of cabozantinib in locally advanced, recurrent and/or metastatic salivary gland cancer patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R, Mitani Y, McGrail DJ, Li K, et al · · 2021 · cited 109× · PMID 33172898 · DOI 10.1158/1078-0432.ccr-20-1192
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.
Di Villeneuve L, Souza IL, Tolentino FDS, Ferrarotto R, et al · · 2020 · cited 61× · PMID 33194707 · DOI 10.3389/fonc.2020.580141
BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8
Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
van Boxtel W, Uijen MJM, Krens SD, Dijkema T, et al · · 2022 · cited 16× · PMID 34920917 · DOI 10.1016/j.ejca.2021.10.033
Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z, Grandis JR, Johnson DE. · · 2022 · cited 10× · PMID 36131561 · DOI 10.1080/14728214.2022.2125954
Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.
Krens SD, van Boxtel W, Uijen MJM, Jansman FGA, et al · · 2022 · cited 10× · PMID 34494665 · DOI 10.1002/ijc.33797
Adenoid cystic carcinoma: insights from molecular characterization and therapeutic advances.
Jia Y, Liu Y, Yang H, Yao F. · · 2024 · cited 7× · PMID 39263605 · DOI 10.1002/mco2.734
Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.
Loddo M, Hardisty KM, Llewelyn A, Haddow T, et al · · 2022 · cited 2× · PMID 35984852 · DOI 10.1371/journal.pone.0246778

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Salivary Gland Cancer

Currently open trials in the same condition.

NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
NCT06805617 — A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers · Phase 2 · recruiting
NCT06695845 — A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors · Phase 2 · recruiting
NCT05553782 — Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers · EARLY_PHASE1 · recruiting
NCT05074940 — Amivantamab in Adenoid Cystic Carcinoma · Phase 2 · active not recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03729297 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 12 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03729297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing